Stocks Health care NEUP
NASDAQ · Health careNeuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. reported revenue of $1.2M in fiscal 2026, down 92.5% from a year earlier. It posted a net loss of $13.5M. At June 30, 2026 it held $19.9M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 18, 2026.
Key facts about Neuphoria Therapeutics Inc.
- Net worth
- Neuphoria Therapeutics Inc. has a market value (market cap) of $14.6M at the latest share price, and shareholders' equity of $24.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $1.2M (-92.5% year on year), with a net loss of $13.5M.
- Cash flow
- In fiscal 2026 operations used $12.4M of cash.
- Latest report
- The latest periodic report (annual report, 10-K) was filed with the SEC on September 18, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Neuphoria Therapeutics Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Neuphoria Therapeutics Inc. does
Neuphoria Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NEUP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $1.2M | -$13.5M | -$3.06 | n/a |
| 2025 | $15.6M | -$369.6K | -$0.23 | n/a |
| 2024 | n/a | -$15.5M | -$18.62 | n/a |
| 2024 | n/a | -$21.4M | -$37.24 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NEUP ranks in Health care
Latest SEC filings
What Neuphoria Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Passive stake (5% or more) SCHEDULE 13G
- September 18, 2026Additional proxy material DEFA14A
- September 18, 2026Additional proxy material DEFA14A
- September 18, 2026Proxy statement DEF 14A
- September 18, 2026Annual report10-K · period to June 30, 2026Neuphoria restructured operations and agreed to be acquired by Scancell after its lead drug candidate failed a Phase 3 clinical trial.Revenue fell 92% to $1.2M versus the prior year; diluted EPS -$3.06 versus -$0.23.
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 24, 2026Additional proxy material DEFA14A
- July 24, 2026
- May 26, 2026Other event 8-K
- May 15, 2026
Insider trades
What the people running Neuphoria Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns NEUP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lynx1 Capital Management LP13D, may seek influence with 1 related filers | 16.3% | December 29, 2025 |
| Shay Capital LLC13G, passive with 1 related filers | 7.3% | October 31, 2025 |
| AdvisorShares Trust13G, passive | 5.78% | October 5, 2026 |
Largest institutional holders
Insiders
Questions about NEUP
What does Neuphoria Therapeutics Inc. do?
Neuphoria Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as NEUP. Its shares trade on NASDAQ under the ticker NEUP.
What is Neuphoria Therapeutics Inc.'s net worth?
Neuphoria Therapeutics Inc. has a market value (market cap) of $14.6M at the latest share price, and shareholders' equity of $24.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Neuphoria Therapeutics Inc. profitable?
No. In fiscal 2026 it reported a net loss of $13.5M on revenue of $1.2M.
How much revenue does Neuphoria Therapeutics Inc. make?
In fiscal 2026 Neuphoria Therapeutics Inc. reported revenue of $1.2M. That is 92.5% less than a year earlier.
When did Neuphoria Therapeutics Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on September 18, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 5, 2026.
When is Neuphoria Therapeutics Inc.'s next earnings report?
Neuphoria Therapeutics Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NEUP with
Follow NEUP
Get an email when Neuphoria Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Neuphoria Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.